Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13285102 | 0.80 | SLC6A4 (0.48) | CHRNB2CHRNA4CYP2A6SLC6A2SLC6A4 | |
| SCHEMBL873728 | 0.78 | CYP2E1 (0.49) | CYP2A6 | |
| SCHEMBL14945019 | 0.76 | TAAR1 (0.52) | HTR6CHRNA7TAAR1CYP2A6 | |
| SCHEMBL6628774 | 0.76 | TKT (0.39) | CYP2A6 | |
| SCHEMBL2982329 | 0.75 | HTR6 (0.48) | HTR6CHRNA7TAAR1CHRNB2CHRNA4 | |
| SCHEMBL21983945 | 0.74 | TAAR1 (0.50) | TAAR1 | |
| SCHEMBL18924363 | 0.74 | TDP1 (0.43) | CYP2A6HRH3 | |
| SCHEMBL320336 | 0.74 | HTR6 (0.47) | HTR6CHRNA7IDO1 | |
| SCHEMBL214076 | 0.73 | — | — | |
| SCHEMBL30753498 | 0.72 | ADAMTS4 (0.34) | CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | HTR6 2026/4885CHRNA7 4696/4885TAAR1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.